158 related articles for article (PubMed ID: 25688232)
1. Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality.
Sugiyama T; Torio T; Sato T; Matsumoto M; Kim YT; Oda H
Front Endocrinol (Lausanne); 2015; 6():6. PubMed ID: 25688232
[No Abstract] [Full Text] [Related]
2. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
Saito M; Marumo K
Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
[TBL] [Abstract][Full Text] [Related]
3. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
Marumo K; Saito M
Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
[TBL] [Abstract][Full Text] [Related]
4. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.
Zanchetta JR; Bogado CE; Ferretti JL; Wang O; Wilson MG; Sato M; Gaich GA; Dalsky GP; Myers SL
J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
6. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
7. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
Skiba K; Adamczak M; Wiecek A
Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
[TBL] [Abstract][Full Text] [Related]
8. Bone's mechanostat: a 2003 update.
Frost HM
Anat Rec A Discov Mol Cell Evol Biol; 2003 Dec; 275(2):1081-101. PubMed ID: 14613308
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone (1-84) and teriparatide in the treatment of postmenopausal osteoporosis.
Bogado CE; Massari FE; Zanchetta JR
Womens Health (Lond); 2006 May; 2(3):447-57. PubMed ID: 19803916
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
13. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
Ohtori S; Inoue G; Orita S; Yamauchi K; Eguchi Y; Ochiai N; Kishida S; Kuniyoshi K; Aoki Y; Nakamura J; Ishikawa T; Miyagi M; Kamoda H; Suzuki M; Kubota G; Sakuma Y; Oikawa Y; Inage K; Sainoh T; Takaso M; Toyone T; Takahashi K
Spine (Phila Pa 1976); 2013 Apr; 38(8):E487-92. PubMed ID: 23354115
[TBL] [Abstract][Full Text] [Related]
14. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis.
Ebeling PR; Russell RG
Int J Clin Pract; 2003 Oct; 57(8):710-8. PubMed ID: 14627183
[TBL] [Abstract][Full Text] [Related]
16. Biomechanics of bone: determinants of skeletal fragility and bone quality.
Turner CH
Osteoporos Int; 2002; 13(2):97-104. PubMed ID: 11905527
[TBL] [Abstract][Full Text] [Related]
17. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
[TBL] [Abstract][Full Text] [Related]
18. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
19. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
20. The role of teriparatide in sequential and combination therapy of osteoporosis.
Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
